alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › immunotherapy

immunotherapy

2 studies tagged immunotherapy, dated 2016-12-23 to 2024-07-06. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease 2024-07-06
  2. Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study 2016-12-23

Studies

2 studies carry this tag.

Date range

2016 to 2024

Top journals

  • Alzheimer's & dementia (New York, N. Y.) 1
  • Alzheimer's research & therapy 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's research & therapy 2024-07-06 Biomarkers

    Potential DMT candidates at Butler MAP (n = 50), primarily diagnosed with mild cognitive impairment (n = 29 [58%]) or mild dementia (21 [42%]), were predominantly Aβ-positive (38 [76%]), and half (25 [50%]) were subsequently treated with aducanumab.

  2. Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia (New York, N. Y.) 2016-12-23 Brain scans and imaging

    Repeated CAD106 administration was generally well tolerated.

All topic tags with their study counts